Sumit Chanda - Mobilizing an International Research Team Against COVID-19 (EP.02)
Sumit Chanda and Daniel Haders II, Ph.D. continue with Ep. 2 of their four-part discussion by detailing how the Chanda lab mobilized scientists from all over the world early in the pandemic to study SARS-CoV-2, the virus that causes COVID-19. Dr. Chanda discusses this major international research collaboration, its focus on discovering broad spectrum antivirals, as well as the groundbreaking results of the study published in Nature.
Model Medicines recently partnered with the Chanda Lab at Sanford Burnham Prebys Medical Discovery Institute to discover and develop new treatments for COVID-19 and other infectious diseases.
Sumit Chanda earned his Ph.D from Stanford University in 2001, and received his post-doctoral training at the Genomics Institute of the Novartis Research Foundation (GNF). He subsequently transitioned to a Group Leader position, and established his research group in the Division of Cellular Genomics at GNF. In 2007, he joined the Infectious and Inflammatory Disease Center at Sanford-Burnham Medical Research Institute as an Associate Professor. Dr. Chanda was promoted to Professor in 2013. In 2015, he was appointed Director of the Immunity and Pathogenesis Program at Sanford Burnham Prebys Medical Discovery Institute.
